SUPERB Trial

Michel M.P.J. Reijnen, MD, PhD Vascular Surgeon, Rijnstate Hospital, Arnhem, The Netherlands. Issue Volume 14 – Issue 8 – August 2017 Citation Vascular Disease Management. 2017;14(8):e189-e191. The SUPERB Study The SUPERB trial is a multicenter randomized trial that was designed to prove the concept of endoluminal bypass with the heparin-bonded Gore Viabahn self-expanding endoprosthesis in… Read More »

Vascular Successful results for Aortica’s AortaFit FEVAR planning software

     Benjamin Starnes, chief of Vascular Surgery at the University of Washington (Seattle, USA), has reported successful results for the first 30 patients undergoing fenestrated endovascular aneurysm repair (FEVAR) planned and performed using Aortica’s AortaFit automated case planning software. The cases are part of Starnes’ US Food and Drug Administration (FDA)-approved physician-sponsored investigational device exemption… Read More »

Radiation During EVAR Damages Operators’ DNA

A study published in Circulation has shown for the first time that an acute DNA damage response occurs in operators performing fluoroscopically-guided interventions such as endovascular aortic repair (EVAR). Leg shielding may have a protective effect though, the researchers said. DNA damage/repair markers were measured in circulating lymphocytes of operators at several times—before performing endovascular and open… Read More »

Takeaways from Recent Data on Superficial Femoral Artery

  Superficial femoral artery (SFA) is an area of intense research interest and multiple options for treatment. In this Q&A, Gary Ansel, MD, FACC, explains the takeaways from recently released data on various devices and therapies. Dr Ansel is an interventional cardiologist at Riverside Methodist Hospital in Columbus, Ohio, and he is a faculty member… Read More »

Precommercialisation of Serpentis drug-eluting stent announced

Stentys has announced the precommercialisation of its Serpentis stent. According to a press release, the sirolimus-eluting stent has a biodegradable coating and is designed for routine procedures. Now that the device has the CE mark, Stentys plans for the stent to be precommercialised by the end of the year to a selection of pilot centres… Read More »

Positive 24-month TOBA Results

  Intact Vascular has announced that positive single centre twenty-four month results from its TOBA(Tack optimised balloon angioplasty) clinical study were presented at VEITHsymposium 2017 by Christian Wissgott, assistant director, Westküstenklinikum Heide in Heide, Germany. The multicentre TOBA study enrolled 138 patients with femoropopliteal peripheral arterial disease in Europe. All participants underwent percutaneous balloon angioplasty and repair of… Read More »

CMS Decision May Threaten DCB Utilization

 Hello and welcome to the November edition of Vascular Disease Management. There are excellent articles in this edition, but I’ve chosen to deviate from the standard practice of commenting on one of these articles. I have instead decided to comment on drug-coated balloon (DCB) technology as there are now 3 FDA-approved devices, with many others… Read More »

Serranator Alto serration balloon effective at 30 days in treating critical femoropopliteal lesion

Preliminary 30-day data from the PRELUDE trial investigating the use of the Serranator Alto percutaneous transluminal angioplasty (PTA) serration balloon catheter (Cagent Vascular) have shown 100% technical success and good effectiveness in moderate to severe calcification in the superficial femoral artery. The acute results show that the balloon can achieve low residual stenosis, and final… Read More »